文献速递淋巴瘤

伴与不伴t(14;18)的滤泡性淋巴瘤亚组N-糖基化模式及IGHV使用差异

Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage.
PubMed 文献 · Blood Adv · 2021-01-01

该研究采用下一代测序对68例新鲜冻存滤泡性淋巴瘤(FL)[36例t(14;18)阳性、32例t(14;18)阴性]进行克隆型分析,涵盖早期(I/II)和晚期(III/IV)初治及复发肿瘤。结果显示t(14;18)阳性与阴性FL在III/IV期新获得N-糖基化位点(NANGS)频率差异显著,而I/II期无差异;t(14;18)阴性各临床亚组NANGS更常引入FR3区,且初治t(14;18)阴性伴NANGS者IGHV4-34使用明显偏倚,复发FL中未记录到IGHV4-34使用。

要点

  • t(14;18)阳性与阴性FL的NANGS频率差异仅见于III/IV期,I/II期无差异。
  • t(14;18)阴性FL各亚组NANGS更常引入FR3区。
  • 初治t(14;18)阴性伴NANGS者IGHV4-34使用偏倚,提示自身抗原反应性。

核心结论

  • t(14;18)阴性FL亚组可能采用不同于t(14;18)阳性FL(凝集素介导结合)的BCR刺激机制,包括对自身抗原的反应性。

研究设计与样本

  • 采用下一代测序方法对68例新鲜冻存FL材料(36例t(14;18)阳性、32例t(14;18)阴性)确定克隆型,涵盖早期(I/II)和晚期(III/IV)初治及复发肿瘤。

主要发现

  • t(14;18)阳性与阴性FL在III/IV期的NANGS频率差异显著,而I/II期无差异。
  • 所有t(14;18)阴性临床亚组中NANGS更常引入FR3区。
  • 初治t(14;18)阴性伴NANGS的FL较t(14;18)阳性伴NANGS初治病例显示IGHV4-34使用的强烈偏倚。
  • 复发FL中从未记录到IGHV4-34使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We previously reported that t(14;18)-negative follicular lymphomas (FL) show a clear reduction of newly acquired N-glycosylation sites (NANGS) in immunoglobulin genes. We therefore aimed to investigate in-depth the occurrence of NANGS in a larger cohort of t(14;18)-positive and t(14;18)-negative FL, including early (I/II) and advanced (III/IV) stage treatment-naive and relapsed tumors. The clonotype was determined by using a next-generation sequencing approach in a series of 68 FL with fresh frozen material [36 t(14;18) positive and 32 t(14;18) negative]. The frequency of NANGS differed considerably between t(14;18)-positive and t(14;18)-negative FL stage III/IV, but no difference was observed among t(14;18)-positive and t(14;18)-negative FL stage I/II. The introduction of NANGS in all t(14;18)-negative clinical subgroups occurred significantly more often in the FR3 region. Moreover, t(14;18)-negative treatment-naive FL, specifically those with NANGS, showed a strong bias for IGHV4-34 usage compared with t(14;18)-positive treatment-naive cases with NANGS; IGHV4-34 usage was never recorded in relapsed FL. In conclusion, subgroups of t(14;18)-negative FL might use different mechanisms of B-cell receptor stimulation compared with the lectin-mediated binding described in t(14;18)-positive FL, including responsiveness to autoantigens as indicated by biased IGHV4-34 usage and strong NANGS enrichment in FR3.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Leich E, Maier C, Bomben R, et al. Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage. Blood Adv. 2021. PMID: 34614504. doi:10.1182/bloodadvances.2021005081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。